Evidence map›Paper›PMID 39373949›Full record

ArticleInfection2025

Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol.

Janina Trauth, Rahel Schuler, Markus Waitz, Harald Ehrhardt, Moritz Fritzenwanker, Susanne Herold

Erratum issuedAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Successful sequential therapy forFrontiers in pediatrics · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Janina TrauthDepartment of Medicine V - Internal Medicine, Infectious Diseases & Infection Control, Justus- Liebig-University, member of the German Center for Lung Research (DZL) and German Center for Infection Research (DZIF) and Cardio-Pulmonary Institute (CPI), Giessen, Germany. janina.trauth@innere.med.uni-giessen.de.ORCID http://orcid.org/0000-0002-1959-7295
Rahel SchulerDepartment of General Pediatrics and Neonatology, Justus Liebig University, Giessen, Germany.
Markus WaitzDepartment of General Pediatrics and Neonatology, Justus Liebig University, Giessen, Germany.
Harald EhrhardtDepartment of General Pediatrics and Neonatology, Justus Liebig University, Giessen, Germany.
Moritz FritzenwankerInstitute of Medical Microbiology, Justus Liebig University Giessen, Giessen, Germany.
Susanne HeroldDepartment of Medicine V - Internal Medicine, Infectious Diseases & Infection Control, Justus- Liebig-University, member of the German Center for Lung Research (DZL) and German Center for Infection Research (DZIF) and Cardio-Pulmonary Institute (CPI), Giessen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefiderocol is a new siderophore-beta-lactam antibiotic used for the treatment of severe multidrug-resistant infections like sepsis, hospital-acquired and ventilator-associated pneumonia in adults, but there are only single reports on its use in the neonatal population. We describe the successful cefiderocol treatment of a newborn with pneumogenic sepsis due to Stenotrophomonas maltophilia.

Indexed as

Anti-Bacterial AgentsCephalosporinsCross InfectionGram-Negative Bacterial InfectionsHealthcare-Associated PneumoniaPneumonia, BacterialStenotrophomonas maltophiliaCefiderocolFemaleHumansInfant, NewbornTreatment OutcomeAnti-Bacterial AgentsCefiderocolCephalosporinsCefiderocolMulti drug resistanceNeonatePneumogenic sepsisStenotrophomonas maltophilia

Identifiers

PMID39373949
PMCPMC12137400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.